The Food and Drug Administration has cleared Neuralink to implant its brain chip in a second patient after the company reportedly outlined fixes to an electrode problem that limited the device's functionality in the first human test subject.
Why it matters: It's another step forward for brain-computer interface devices that companies hope will someday treat neurological disorders.
The financial promise of weight-loss drugs is giving another company a boost: This time it's Hims & Hers.
Zoom in: The telehealth company's stock soared over 27% Monday after it said it would begin selling compounded versions of the GLP-1 injections that are soaring in popularity.
Delaware will test a Medicaid program allowing delivery of meals and diapers to postpartum enrollees for three months after giving birth.
Why it matters: The pilot program approved by the Centers for Medicare and Medicaid Services on Friday is the latest effort to expand coverage of social supports aimed at improving the health of Medicaid beneficiaries.
A new chapter in drug advertising begins Monday when a federal transparency rule takes effect requiring commercials to clearly spell out potential side effects and when a person should avoid the medicine.
Why it matters: The effort, more than a decade in the making, could demystify those rapid-fire disclaimers at the end of TV and radio ads through steps like simultaneous text that is displayed long enough to be read easily.
Marijuana could get easier to study following the Biden administration's move to reclassify it as a less dangerous drug, but scientists say research barriers won't entirely disappear.
Why it matters: Even as most Americans live in states that have legalized marijuana, stringent federal requirements have limited research on its uses and effects.
Consumers, especially the rich, are spending big on the colossal, growing longevity industry — spas, food subscriptions, gym memberships and pills.
Why it matters: The wellness industry is worth nearly $500 billion in the U.S. and $2 trillion globally, McKinsey says. But there's a growing gap between what's available to wealthy consumers and everyone else.
